This an illuminating and exciting post from OIL aficionado Graeme Mutton.
To place the $1.35 million revenue in context one needs to consider that
just a handful of hospitals, carefully selected by Zeiss, are using the technology!
The calculation is helpful because it suggests hospitals trialling the new paradigm
are expanding in number.
This brings us closer to that day when Optiscan's technology is accepted as the
global 'Gold Standard' for neuro tumour treatment.
What could this look like arithmetically?
A very rough guide: at least 100 x current early-stage sales = $135 million.
Say a tech. stock multiple of 10 x sales = $1.35 billion = $2.00 plus a share.
Plus Breast + Oral + Gastro + + +
This is why Pangloss is bullish.
He/she declares a meaningful shareholding and this has recently increased.